BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12429815)

  • 1. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones.
    Stoehr R; Knuechel R; Boecker J; Blaszyk H; Schmitt R; Filbeck T; Hofstaedter F; Hartmann A
    Lab Invest; 2002 Nov; 82(11):1553-61. PubMed ID: 12429815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
    Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
    Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
    Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
    Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract.
    Hafner C; Knuechel R; Zanardo L; Dietmaier W; Blaszyk H; Cheville J; Hofstaedter F; Hartmann A
    Oncogene; 2001 Aug; 20(35):4910-5. PubMed ID: 11521204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis.
    Hartmann A; Rösner U; Schlake G; Dietmaier W; Zaak D; Hofstaedter F; Knuechel R
    Lab Invest; 2000 May; 80(5):709-18. PubMed ID: 10830781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
    Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
    Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
    Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
    BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer.
    Stoehr R; Zietz S; Burger M; Filbeck T; Denzinger S; Obermann EC; Hammerschmied C; Wieland WF; Knuechel R; Hartmann A
    Eur Urol; 2005 Jan; 47(1):58-63. PubMed ID: 15582250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.
    Czerniak B; Chaturvedi V; Li L; Hodges S; Johnston D; Roy JY; Luthra R; Logothetis C; Von Eschenbach AC; Grossman HB; Benedict WF; Batsakis JG
    Oncogene; 1999 Feb; 18(5):1185-96. PubMed ID: 10022124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry.
    Yamamoto S; Tada M; Lee CC; Masuda C; Wanibuchi H; Yoshimura R; Wada S; Yamamoto K; Kishimoto T; Fukushima S
    Jpn J Cancer Res; 2000 Feb; 91(2):181-9. PubMed ID: 10761705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular evidence supporting field effect in urothelial carcinogenesis.
    Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
    Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
    Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
    Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of p53 mutations in bladder washings and histologic specimens.
    Vet JA; Hessels D; Marras SA; van de Kaa CA; van der Poel HG; Michalides RJ; Debruyne FM; Schalken JA
    Am J Clin Pathol; 1998 Nov; 110(5):647-52. PubMed ID: 9802351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
    Vet JA; Bringuier PP; Schaafsma HE; Witjes JA; Debruyne FM; Schalken JA
    Lab Invest; 1995 Dec; 73(6):837-43. PubMed ID: 8558845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
    Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
    Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
    Sun W; Zhang PL; Herrera GA
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.